Articles published by Baudax Bio, Inc.
Baudax Bio Announces Pricing of $4 Million Public Offering
April 26, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
April 25, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
April 24, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
March 27, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
February 23, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
January 24, 2023
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
December 08, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Closing of $5 Million Public Offering
December 06, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces Pricing of $5 Million Public Offering
December 02, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Baudax Bio Announces 1-for-40 Reverse Stock Split
November 30, 2022
From Baudax Bio, Inc.
Via GlobeNewswire
Tickers
BXRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.